An internal standard for the quantification of trimetazidine
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Trimetazidine-d8 (hydrochloride)

Item No. 39810

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1-(2,3,4-trimethoxybenzyl)piperazine-2,2,3,3,5,5,6,6-d8, dihydrochloride
CAS Number
1219795-37-5
Molecular Formula
C14H14D8N2O3 • 2HCl
Formula Weight
347.3
Purity
≥99% deuterated forms (d1-d8)
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Slightly solubleMethanol: Slightly solubleWater: Slightly soluble
SMILES
[2H]C1(C([2H])(NC([2H])(C([2H])(N1CC2=C(OC)C(OC)=C(OC)C=C2)[2H])[2H])[2H])[2H].Cl.Cl
InChi Code
InChI=1S/C14H22N2O3.2ClH/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16;;/h4-5,15H,6-10H2,1-3H3;2*1H/i6D2,7D2,8D2,9D2;;
InChi Key
VYFLPFGUVGMBEP-IKGFOUCPSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $101

    Add

    5 mg

    $325

    Add

    10 mg

    $500

    Add

    25 mg

    $999

    Add
    Product Description

    Trimetazidine-d8 is intended for use as an internal standard for the quantification of trimetazidine by GC- or LC-MS. Trimetazidine is a cardioprotective agent.1 It decreases ischemia-reperfusion injury-induced pyroptosis in H9c2 rat cardiomyocytes when used at concentrations ranging from 5 to 100 µM. In vivo, trimetazidine (10 mg/kg) reduces cardiac TNF-α and cardiac troponin I (CTnI) levels, improves left ventricular ejection fraction, and increases survival in a rat model of ventricular fibrillation-induced post-resuscitation myocardial dysfunction.2 Trimetazidine (20 mg/kg) increases overall survival, prevents neuromuscular junction degeneration, and delays motor function decline in an SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS).3 Formulations containing trimetazidine have been used in the treatment of angina.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Chen, X., Lin, S., Dai, S., et al. Trimetazidine affects pyroptosis by targeting GSDMD in myocardial ischemia/reperfusion injury. Inflamm. Res. 71(2), 227-241 (2022).

    2. Li, J., Qi, Y., Wang, J., et al. Trimetazidine alleviates postresuscitation myocardial dysfunction and improves 96-hour survival in a ventricular fibrillation rat model. J. Am. Heart Assoc. 11(6), e023378 (2022).

    3. Scaricamazza, S., Salvatori, I., Amadio, S., et al. Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1G93A mice. Br. J. Pharmacol. 179(8), 1732-1752 (2021).